Endava to Acquire GalaxE Solutions to Boost Its Position in North America Healthcare With Delivery from India
Endava, a leading technology services company combining world-class engineering, industry expertise, and a people-centric mindset, has entered into a definitive agreement to acquire 100% ownership of GalaxE Group, Inc. (GalaxE), a global IT and business solutions provider headquartered in New Jersey, United States.
Founded by Tim Bryan over 30 years ago, GalaxE has been singularly focused on driving digital transformation for Fortune 500 companies in the healthcare, financial services, and retail industries.
When completed, the transaction will add approximately 1,650 employees and provide several key strategic benefits to...
Source: EMR and HIPAA - March 21, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Akin Gump Strauss Hauer & Feld LLP BofA Securities Endava GalaxE GalaxE Group Inc. Health IT Acquisitions Healthcare M&A John Cotterell JP Morgan Securities LLC Tim Bryan White & Case LLP Source Type: blogs
Why ICDs are less effective in Non Ischemic DCM ?
We wish, our understanding about cardiac contractile physiology is deep and nearly complete. Heart is an irreversibly coupled electro-mechanical organ , right from the fetal days until the final heart beat. In myocardial pathology, the genesis and sustainability of ventricular arrhythmia are intricately related to the degree of LV dysfunction of any cause.
SCD is the leading cause of mortality in heart failure. Tackling SCD was in God’s domain, until the brilliance of Dr. Michel Mirowski shrunk the defibrillator and implanted it under the chest in 1980. (Dr. MM’s s a unique and inspiring story, from Poland a...
Source: Dr.S.Venkatesan MD - February 20, 2024 Category: Cardiology Authors: dr s venkatesan Tags: Uncategorized crt device crt-p vs crt-d danish trial ischemic dcm madit trial non ischemic dcm Source Type: blogs
So what can we do about health care costs?
By MATTHEW HOLT
Last week Jeff Goldsmith wrote a great article in part explaining why health care costs in the US went up so much between 1965 and 2010. He also pointed out that health care has been the same portion of GDP for more than a decade (although we haven’t had a major recession in that time other than the Covid 2020 blip when it went up to 19%). However, it’s worth remembering that we are spending 17.3% of GDP while the other main OECD countries are spending 11-12%. Now it’s true that the US has lots of social problems that show up in heath spending and also that those other countries probably spend ...
Source: The Health Care Blog - February 20, 2024 Category: Consumer Health News Authors: matthew holt Tags: Health Policy Matthew Holt Buzz Cooper Datmouth health spending Jeff Goldsmith John Wennberg Medicare Price controls Source Type: blogs
An Urgent Call for AI Solutions to Tap Evidence-Based Research Best Practices
This study is pivotal for showcasing how AI enhances decision-making in critical situations. It finds that AI-supported workflows can outperform traditional stroke decision-making in meaningful and measurable ways to greatly improve time to relevant care.
Notably, as described in the study discussion, “Our results showed that a machine learning framework can substantially improve stroke recognition in medical helpline calls compared to solely relying on human call-takers. This improvement was observed across all performance metrics and for basic patient demographics (age and sex).”
There is Urgency in Establishing Trus...
Source: EMR and HIPAA - January 31, 2024 Category: Information Technology Authors: Guest Author Tags: AI/Machine Learning Analytics/Big Data Clinical Health IT Company Healthcare IT ACV AI Solutions Ambient Clinical Voice Corti DTU Evidence Based Data Lars Maaløe Nature Technical University of Denmark Source Type: blogs
The Business Case for a Biosimilar Company to Bring a Copy of Levemir to Market
My readers may recall that in November 2023, I blogged that Novo Nordisk announced it plans to retire (stop making) its first " Lantus killer " known as Levemir (insulin detemir injection) in the U.S. in 2024 (catch my post at https://blog.sstrumello.com/2023/11/novo-nordisk-to-discontinue-levemir-in.html for more). At the time I learned of the announcement, I was on vacation in Amsterdam, so I just made a note of the development and blogged about it a few weeks later upon my return.Like other patients my age, I have endured the company ' s previous insulin " retirements " . Novo Nordisk ' s time-frame for withdr...
Source: Scott's Web Log - January 25, 2024 Category: Endocrinology Tags: 2024 Biosimilar Levemir Novo Nordisk PBM Source Type: blogs
Fight Aging! Newsletter, January 15th 2024
In conclusion, FMD cycles have high potential to be effective in increasing the toxicity of a range of therapies against ALL and other blood cancers and should be tested in randomized clinical trials, especially in combination with immunotherapy and low toxicity cancer therapies.
In summary, we present a new strategy for improving leukemia treatment by combining FMD with chemotherapy to promote the killing of ALL cells in part by an immune-dependent mechanism. Fasting/FMD has been shown to reduce chemotherapy-associated toxicity in pre-clinical and clinical studies and thus represents a safe and potentially effectiv...
Source: Fight Aging! - January 14, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Another Large Study of Hearing Aid Use Shows Deafness Increases Dementia Risk
You might compare the research noted here with another similar study published a year ago. In both cases, data on hearing aid use in large patient populations is used to demonstrate that hearing loss contributes to the onset and progression of dementia. This data doesn't favor any specific theory regarding the mechanism, such as atrophy of brain structures resulting from disuse versus some form of maladaptive compensatory activity in the brain. Greater understanding of the mechanisms involved will require further research.
Hearing loss has been suggested as a risk factor for dementia, but there is still a need for...
Source: Fight Aging! - January 10, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
5 Things We Learnt About Investments In Digital Health: Our E-book
At The Medical Futurist (TMF), and especially at The Medical Futurist Institute, we don’t usually deal with investment-related news and announcements. We receive many press releases coming from incubators and venture capital firms each week, but we never share them on our channels. Even though we focus on technologies and trends rather than companies of interest to investors, this doesn’t mean that we don’t keep a close eye on all these developments.
We are in close contact with many digital health startup founders, analyze the technologies they work on and objectively share news relevant to investors. A...
Source: The Medical Futurist - December 19, 2023 Category: Information Technology Authors: Pranavsingh Dhunnoo Tags: Artificial Intelligence in Medicine Biotechnology Health Sensors & Trackers MySugr theranos invest portable diagnostics Gary rule Kardia CliniCloud tmfi alivecor MagicLeap covid19 digital health investors pandemic ecg R Source Type: blogs
Novo Nordisk to Discontinue Levemir in 2024
Upgrade to Patent-Protected Tresiba — or else!On Wednesday, November 8, 2023, Novo Nordisk announced that it would discontinue its long-acting insulin Levemir (insulin detemir injection) in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The company ' s official statement (seehttps://www.novomedlink.com/diabetes/products/treatments/levemir.html) said: " We will continue to provide Levemir FlexPen and Levemir vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected. "It added further: " Levemir FlexPen,...
Source: Scott's Web Log - November 29, 2023 Category: Endocrinology Tags: 2023 basal insulin diatribe discontinue insulin detemir Levemir Novo Nordisk Source Type: blogs
Ozempic Seems To Be Getting A Lot Of Attention. Care Is Required With On-Line Sales And Marketing At Least!
Fads are a
commonly seen manifestation in the health sector.
It could be
argued to latest biggie is semaglutide (Ozempic). The drug was introduced as a
treatment for Type 2 diabetes but it is the powerful weigh-loss effects that
have been noticed in the overweight rich world – which now has a shortage and which has the drug selling in such quantities that it is having a real impact on the Danish (Source: Australian Health Information Technology)
Source: Australian Health Information Technology - October 17, 2023 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Fight Aging! Newsletter, August 7th 2023
In conclusion, here, we demonstrate a novel mechanism for ESC-EVs to protect cells from senescence. However, whether ESC-EVs rejuvenate aged mice via miR-15b-5p and miR-290a-5p remains unknown. Next, we plan to use miR-15b-5p and miR-290a-5p antagonists while treating aged mice with ESC-EVs to further investigate the mechanism by which ESC-EVs resist aging in vivo.
« Back to Top
Fatty Acid Metabolism as a Commonality in Different Approaches to Slowing Aging
https://www.fightaging.org/archives/2023/08/fatty-acid-metabolism-as-a-commonality-in-different-approaches-to-slowing-aging/
It seem...
Source: Fight Aging! - August 6, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Postmenopausal Hormone Treatment Correlates with Increased Dementia Risk
We report a nationwide study on the association between menopausal hormone therapy and development of dementia. 5,589 incident cases of dementia and 55,890 age matched controls were identified between 2000 and 2018 from a population of all Danish women aged 50-60 years in 2000 with no history of dementia or contraindications for use of menopausal hormone therapy.
Compared with people who had never used treatment, people who had received oestrogen-progestin therapy had an increased rate of all cause dementia (hazard ratio 1.24). Increasing durations of use yielded higher hazard ratios, ranging from 1.21 for one year ...
Source: Fight Aging! - July 31, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
ChatGPT In Healthcare: What Science Says
This study demonstrates that ChatGPT, a large language model, can assist in radiologic decision-making at the point of care, achieving moderate to high accuracy in determining appropriate imaging steps for breast cancer screening and breast pain evaluation, although limitations of the model, such as misalignment and “hallucinations”, must be considered when designing clinically-oriented prompts for use with large language models.Analysis of large-language model versus human performance for genetics questionsMedrxivThe use of language models like ChatGPT in clinical genetics has the potential to provide rapid an...
Source: The Medical Futurist - May 25, 2023 Category: Information Technology Authors: Pranavsingh Dhunnoo Tags: TMF Artificial Intelligence in Medicine ChatGPT digital health large language models ChatGPT in healthcare AI in healthcare AI in medicine Source Type: blogs
Steroids And The Heart: A Revealing Study On Long-Term Risks
Conclusion: A Heartfelt Wake-Up Call
These pioneering studies serve as a stark reminder that every choice has consequences – and when it comes to anabolic steroids, those consequences can be heart-wrenching.
The results underscore the urgency of prioritizing health over fleeting performance gains.
As we step forward, awaiting more insights from larger studies, remember – your health is an invaluable asset, one that deserves more than temporary boosts.
Making conscious, informed choices today can shield your heart from undue harm tomorrow.
References
American Heart Association: Steroids, Other A...
Source: The EMT Spot - May 15, 2023 Category: Emergency Medicine Authors: Michael Rotman, MD, FRCPC, PhD Tags: News Source Type: blogs
Democracies, Autocracies, and Same ‐Sex Unions
David BoazA new study by the Indian newspaperThe Print, based on data fromThe Economist Intelligence Unit ’s Democracy Index 2022, finds that 88 percent of full democracies recognize same‐sex marriages or civil unions, while only 2 percent of authoritarian regimes do.As my colleague Swaminathan Aiyar told the paper, “Autocracies do not recognise individual rights as fundamental and inalienable. Autocracies are organised on principles that allow the autocrat to discriminate on any grounds. In such countries, the progress of same‐sex rights will naturally be slower or non‐existent.” By contrast, imp lem...
Source: Cato-at-liberty - May 3, 2023 Category: American Health Authors: David Boaz Source Type: blogs
